CTIS2023-503688-41-00招募中1 期
Efficacy of Vitex agnus-castus BNO 1095 (20 mg) in women with primary dysmenorrhea - AgnoMed
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bionorica SE
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Women aged 18-49 years who have the capacity for consenting, Patient has been informed of the nature, scope, and relevance of the clinical trial, voluntary agrees in participation and the trial provisions, and has duly signed the approved informed consent form (ICF), Diagnosed primary dysmenorrhea (see Section 5.1, Table 1), If patients take pain relief medication for primary dysmenorrhea, this medication should be taken unchanged with regard to application form and kind of medication including strength … [due to commercially confidential information restrictions]. Note: Medication (drugs) for primary dysmenorrhea as mono- or combination therapy in form of tablets/capsules regularly used by the patient before Screening is allowed to be used as standard pain relief medication during the trial apart from non-medication methods. A complete list of allowed pain relief medication is attached to the protocol (Appendix 2). … [due to commercially confidential information restrictions]., Patients with a regular menstrual cycle duration of =24 to =38 days, Patients agreeing to use one of the following contraception methods throughout the trial: a. Bilateral tubal occlusion b. Vasectomized partner (provided that the partner is the sole sexual partner of the woman and has received medical assessment of the surgical success) c. Sexual abstinence Abstinence is only accepted as true abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal) is not an acceptable method of contraception. d. Male or female condom with or without spermicide e. Cap, diaphragm, or sponge with spermicide.
排除标准
- •Non-menstruating women, Known or suspected acute infection of gonorrhea, syphilis and/or chlamydia at Screening, Current or past estrogen sensitive cancer or pituitary disorder that, in the investigator’s opinion, would make the patient not suitable for the trial., Women who are breastfeeding, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the trial., Fewer than 3 menstrual cycles before Screening following delivery, abortion, miscarriage, or lactation., Current severe physical or mental illness., Patient does not agree to avoid daily smoking., History of alcohol, drug, or medicine abuse within 1 year prior to Screening, or positive for drugs or medicines of abuse in the laboratory analysis performed at Screening., Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption., Hypersensitivity to Vitex agnus-castus, lactose or any of the excipients of the IMP or to any ingredients of the standard pain relief medication., Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities., Clinically diagnosed secondary dysmenorrhea (e.g., fibroids, uterine adenomyosis, endometriosis, pelvic inflammation, ovarian pathologies, or other pelvic diseases), Employees of the sponsor or site staff or direct relatives of the site staff., Legal incapacity or limited legal capacity., Patients not able to follow trial instructions or assessments or to participate in the trial … [due to commercially confidential information restrictions] or unable to understand written and verbal instruction, in particular regarding the risks and inconveniences that the patients will be exposed to during participation in the clinical trial., Participation in another interventional clinical trial during the last month before Screening., Use of Vitex agnus-castus containing preparation or product within the last 3 months before Screening., Current intake or intake within the last 4 weeks before Screening of dopamine agonists, dopamine antagonists, estrogens, or antiestrogens that would make the patient not suitable for the trial., Dysmenorrhea resulting from the use of an intrauterine device., Use of hormonal contraceptives (oral, intravaginal, transdermal, injectable, implantable), intrauterine device, or intrauterine hormone-releasing system within 6 months prior to the trial and not willing to waive it during the entire trial period., Any surgical treatments in the past (e.g., due to myoma) that may cause pain, adhesions or scarring in the lower abdomen Note: Further diagnostic examination (e.g., laparoscopy for differential diagnosis, exclusion of endometriosis) if deemed necessary by the investigator will be outside the trial protocol and reimbursement., Known or suspected gastrointestinal or urological conditions that may cause abdominal and/or pelvic pain, such as colitis, appendicitis, irritable bowel syndrome, cholelithiasis, interstitial cystitis, cystitis, urolithiasis, and other conditions that, according to the investigator’s judgement, are not suitable for the trial., Known or suspected gynecological complaints e.g., premenstrual abdominal pain, deep dyspareunia, uterine fibroids and polyps, or chronic pain (abdominal, dorsal, urogenital)., Known instable diseases e.g., psychiatric, cardiovascular, or endocrine disorders., Body mass index <18.5 or >34.9 kg/m² at Screening.
研究者
相似试验
已完成
3 期
Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary DysmenorrheaPrimary DysmenorrheaNCT06211049Bionorica SE335
已完成
不适用
Evaluating the effect of vitex agnus castus on treatment of premenstrual syndromePremenstrual syndrome.Premenstrual tension syndromeIRCT201101035541N1Tehran University of Medical Sciences116
已完成
2 期
The Effect of Vitex Agnus Castus Extract on Blood Level of Prolactin & It,s Hormonal, Metabolic & Histological Effects in Comparison with Bromocriptin & Dostinex in Hyperprolactinemic WomeHyperprolactinemia..IRCT20200118046171N1Islamic Azad University105
已完成
不适用
The effect of the combination of vitex agnus castus`s phytoestrogen and magnesium on fracture healing.Condition 1: Fracture of shaft of femur. Condition 2: Fracture of shaft of tibia. Condition 3: Fracture of shaft of humerus. Condition 4: Fracture of shafts of both ulna and radius.Fracture of shaft of femurFracture of shaft of tibiaFracture of shaft of humerusFracture of shafts of both ulna and radiusIRCT2012092810955N1Shiraz University of Medical Sciences64
尚未招募
不适用
Efficacy of Vitoss versus Vitoss BA in the treatment of Tibial- and Femoral Non-UnioM84.1Nonunion of fracture [pseudarthrosis]DRKS00013563Klinik für Orthopädie und Unfallchirurgie, Universitätsklinikum Heidelberg,Abteilung für UnfallchirurgieProf. Dr. med. Gerhard Schmidmaier60